Parenteral nutrition (PN) provides lifesaving nutrition to infants and children unable to feed enterally. Its use, however, may be complicated by parenteral nutrition-associated liver disease (PNALD). Experts present the pathogenesis of PNALD; PN improvements over the past few decades for hepatic protection;&nbsp;and current research updates in PNALD.<br />
<br />
&nbsp;

This session explores the ways that practicing hepatologists and trainees can incorporate clinical informatics into their careers. Discussion leaders cover the breadth of informatics engagement including: how to obtain additional training and education in informatics; learning how to use and create tools to optimize electronic health record workflows; participation in system-level informatics governance; and clinical research and quality improvement using electronic health record data and informatics tools. The session also addresses how to get involved in clinical informatics fellowships, pathways to clinical informatics board certification, and career options for the hepatologist with an interest or expertise in clinical informatics.

Organ access continues to evolve and is a primary challenge in caring for patients with chronic liver disease. Liver transplant indications in adults have changed over the past decade with the rise of MASLD and the decline of hepatitis C. The landscape of organ availability has concurrently shifted, including national policies, expansion of donor criteria, machine perfusion, and living donor transplant. To highlight the role of living donor transplant in this evolving context, this academic debate session features teams of hepatology trainees and practicing hepatologist debating the pros and cons of the question:&nbsp;Is there a role for living donor liver transplant in adult patients in the age of machine perfusion? The pro position argues that living donor transplant is effective and relevant; the con position argues that living donor transplant will no longer be needed. Debaters, judges, and attendees grapple with opposing scientific, societal, individual, and financial viewpoints on this timely issue.<br />
<br />
<strong>Slido:&nbsp;<a href="https://app.sli.do/event/378zi69nJXst1qhp2f1xqx">https://app.sli.do/eve…;

A panel of editors from <em>Hepatology</em>, <em>Hepatology Communications</em>, and <em>Liver Transplantation</em> offer expert advice on streamlining both prepublication and postpublication processes. Panelists share&nbsp;valuable tips to help authors with their publications by effectively presenting their research to editors, reviewers, and readers. Topics include study design, manuscript preparation, addressing reviewer feedback, and utilizing search engines and social media for optimal postpublication impact.<br />
<br />
&nbsp;<br />
<br />
&nbsp;

This workshop addresses the current state of advanced hepatology training. Speakers discuss salient topics around transplant hepatology training and workforce considerations, including recruitment and participation, retention, funding, and upcoming changes to the American Board of Internal Medicine blueprints. 

<div>Presenters highlight key updates contributing to the simplification of hepatitis C treatment in 2025, including: (1) diagnostic approaches across episodic and long-term health care settings;&nbsp;(2) workup and treatment; and (3) integrated opioid use disorder care and hepatitis C treatment to achieve hepatitis C elimination.</div>

The Associates Course expands the knowledge base of participants to improve patient outcomes in behavioral, nutritional, and pharmacologic interventions in chronic liver disease. Speakers explore topics including: (1) novel treatment models of chronic hepatitis C and MASLD/MASH; (2) pharmacist driven management of chronic liver disease; (3) resource-limited management of chronic liver disease; and (4) palliative approaches to management of patients with chronic liver disease.

Hepatologists are often asked if a patient can restart a medication after an episode of DILI. Utilizing a friendly debate format, presenters highlight key points about the risk/benefit analysis in rechallenge and how to indentify patients suitable for a rechallenge trial. In addition, specific case scenarios with common medications are addressed. Given the nuances involved, the panel comprises stakeholders from academia, the pharmaceutical industry, and regulatory agencies to provide their perspective on the issue of rechallenge after DILI.

The World Health Organization (WHO) has established criteria for elimination of hepatitis B and hepatitis C as public health threats by 2030. Most countries, however, are not on track to meet these WHO goals. Many patients with HBV and/or HCV infection do not have access to treatment, vaccination, or harm reduction efforts. Presenters address the main barriers to viral hepatitis elimination from patient and community perspectives, and strategies to overcome them.<br />
<br />
&nbsp;

Hepatology, cardiology, and transplant medicine experts discuss the pathophysiology, clinical management, and long-term outcomes of Fontan-associated liver disease. The symposium highlights emerging research, diagnostic advancements, and multidisciplinary approaches to improve surveillance, treatment, and transplant decision-making for this unique patient population.&nbsp;Audience members learn from persuasive arguments by transplant surgeons regarding the options of isolated heart transplant versus combined heart-liver transplant for pediatric patients with Fontan failure. Attendees participate in this discussion by questioning presenters and voting how they would handle a challenging clinical case in light of the information presented.<br />
<br />
&nbsp;